國立虎尾科技大學 |

Regulation of Type VII Collagen in Patients with Recessive Dystrophic Epidermolysis Bullosa.

Record Type:	Language materials, manuscript : Monograph/item
Title/Author:	Regulation of Type VII Collagen in Patients with Recessive Dystrophic Epidermolysis Bullosa./
Author:	Vanden Oever, Michael John.
Description:	1 online resource (100 pages)
Notes:	Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.
Contained By:	Dissertation Abstracts International79-10B(E).
Subject:	Immunology. -
Online resource:	click for full text (PQDT)
ISBN:	9780438030787

Regulation of Type VII Collagen in Patients with Recessive Dystrophic Epidermolysis Bullosa.
Vanden Oever, Michael John.

Regulation of Type VII Collagen in Patients with Recessive Dystrophic Epidermolysis Bullosa. - 1 online resource (100 pages)

Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.

Thesis (Ph.D.)--University of Minnesota, 2017.

Includes bibliographical references

Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a complex, life-threatening genetic skin disorder with painful complications. Currently, there is no cure, but there have been recent developments in both the basic biological research aspects and the translational therapies which make effectively treating this disease more likely in the near future. These advances include the use of stem cells and gene editing as well as new insights into the molecular mechanisms for certain aspects of RDEB pathology. The overall goals of our lab are to better define and characterize RDEB pathology, develop novel approaches for treating RDEB, and to improve upon the ways in which we analyze and understand the outcomes of those therapies. These goals are inherently dependent upon a comprehensive understanding of how type VII collagen is regulated, both during the normal wound healing process and over the course of therapeutic intervention.

Electronic reproduction.
Ann Arbor, Mich. :
ProQuest,
2018

Mode of access: World Wide Web

ISBN: 9780438030787Subjects--Topical Terms:

592892
Immunology.
Index Terms--Genre/Form:

554714
Electronic books.

Regulation of Type VII Collagen in Patients with Recessive Dystrophic Epidermolysis Bullosa.
LDR:03092ntm a2200349Ki 4500 001 916325
005 20181002081323.5
006 m o u
007 cr mn||||a|a||
008 190606s2017 xx obm 000 0 eng d
020 $a 9780438030787
035 $a (MiAaPQ)AAI10622401
035 $a (MiAaPQ)umn:18511
035 $a AAI10622401
040 $a MiAaPQ $b eng $c MiAaPQ $d NTU
100 1 $a Vanden Oever, Michael John. $3 1190011
245 1 0 $a Regulation of Type VII Collagen in Patients with Recessive Dystrophic Epidermolysis Bullosa.
264 0 $c 2017
300 $a 1 online resource (100 pages)
336 $a text $b txt $2 rdacontent
337 $a computer $b c $2 rdamedia
338 $a online resource $b cr $2 rdacarrier
500 $a Source: Dissertation Abstracts International, Volume: 79-10(E), Section: B.
500 $a Adviser: Tolar Jakub.
502 $a Thesis (Ph.D.)--University of Minnesota, 2017.
504 $a Includes bibliographical references
520 $a Recessive Dystrophic Epidermolysis Bullosa (RDEB) is a complex, life-threatening genetic skin disorder with painful complications. Currently, there is no cure, but there have been recent developments in both the basic biological research aspects and the translational therapies which make effectively treating this disease more likely in the near future. These advances include the use of stem cells and gene editing as well as new insights into the molecular mechanisms for certain aspects of RDEB pathology. The overall goals of our lab are to better define and characterize RDEB pathology, develop novel approaches for treating RDEB, and to improve upon the ways in which we analyze and understand the outcomes of those therapies. These goals are inherently dependent upon a comprehensive understanding of how type VII collagen is regulated, both during the normal wound healing process and over the course of therapeutic intervention.
520 $a To that aim, we set out to understand two aspects of regulation of type VII collagen that were poorly understood: one focused on the nature of type VII collagen regulation during wound healing and the other focused on type VII collagen regulation during the hematopoietic stem cell transplantation process. We identified a particular micro RNA, miR-29, which regulates COL7A1 transcriptionally and post-transcriptionally. We also demonstrated that fludarabine, a key component of the hematopoietic cell transplantation (HCT) preparative regimen, modulates type VII collagen expression during hematopoietic stem cell transplantation. Our studies have identified a novel mechanism of regulation for type VII collagen that will hopefully give valuable insight into how to treat RDEB, ameliorate RDEB pathology, and properly evaluate clinical outcomes in patients that have receive HCT to treat RDEB.
533 $a Electronic reproduction. $b Ann Arbor, Mich. : $c ProQuest, $d 2018
538 $a Mode of access: World Wide Web
650 4 $a Immunology. $3 592892
650 4 $a Biology. $3 599573
655 7 $a Electronic books. $2 local $3 554714
690 $a 0982
690 $a 0306
710 2 $a ProQuest Information and Learning Co. $3 1178819
710 2 $a University of Minnesota. $b Microbiology, Immunology and Cancer Biology. $3 1184285
773 0 $t Dissertation Abstracts International $g 79-10B(E).
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=10622401 $z click for full text (PQDT)